

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia

Lindsay J. Collin,¹ Ming Yan¹, Renjian Jiang ¹, Kevin C Ward¹, Brittany Crawford², Mylin A Torres^{3,4}, Keerthi Gogineni⁵, Preeti D Subhedar⁶, Samantha Puvanesarajah⁷, Mia M Gaudet⁷, Lauren E McCullough¹

Supplementary Table 1. Multivariable-adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for receipt of chemotherapy according to race and Oncotype DX recurrence score (ODX RS) group among non-Hispanic White (NHW) and non-Hispanic Black (NHB) women diagnosed with breast cancer, an Oncotype DX recurrence score from Genomic Health, Inc., 2010–2014 and registered with the Georgia Cancer Registry, excluding those with 1) lymph node positive (1–3 LN+) breast cancer and 2) an ODX RS from GCR and no corresponding score from Genomic Health.

ODX RS	Chemotherapy				Exclude LN+ 1–3 (n=569)	Exclude ODX RS from GCR (n=329)
	NHW		NHB			
	No	Yes	No	Yes		
Low	2212	64	580	20	1.08 (0.65, 1.81)	0.96 (0.55, 1.67)
Intermediate	887	419	256	146	1.04 (0.81, 1.33)	1.01 (0.79, 1.31)
High	54	279	32	143	0.69 (0.42, 1.14)	0.61 (0.33, 1.13)
Age and stage-adjusted						
No Score	3251	1235	877	600	1.33 (1.14, 1.54)	

Supplementary Table 2. Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for breast cancer specific death according to race and Oncotype DX recurrence score (ODX RS) group among non-Hispanic White (NHW) and non-Hispanic Black (NHB) women diagnosed with breast cancer with an Oncotype DX recurrence score from Genomic Health Inc., 2010–2014 and registered with the Georgia Cancer Registry, excluding those with 1) lymph node positive (1–3 LN+) breast cancer and 2) an ODX RS from GCR and no corresponding score from Genomic Health.

ODX RS	NHW Events	NHB Events	Exclude LN+ 1–3 (n=569)	Exclude ODX RS from GCR (n=329)
Low	16	12	2.96 (1.38, 6.37)	3.11 (1.38, 6.99)
Intermediate	39	17	1.40 (0.79, 2.48)	1.43 (0.80, 2.54)
High	14	15	1.94 (0.92, 4.09)	2.48 (1.07, 5.76)

Supplementary Table 3. Age-adjusted and multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for breast cancer specific death according to race and Oncotype DX recurrence score (ODX RS) group using TAILORx cutpoints among non-Hispanic White (NHW) and non-Hispanic Black (NHB) women diagnosed with breast cancer with an Oncotype DX recurrence score, 2010–2014 and registered with the Georgia Cancer Registry (n=5750).

ODX RS	BC mortality	NHW	NHB	Stratum Specific			
		HR (95% CI)	BC mortality	HR (95% CI)	RERI (95% CI)	Age-adjusted	Age and stage adjusted
Low/Intermediate	50	reference	27	2.08 (1.29, 3.33)	reference	2.08 (1.29, 3.33)	2.10 (1.31, 3.37)
High	30	3.52 (2.23, 5.55)	23	6.32 (3.84, 10.43)	1.73 (-1.28, 4.74)	1.80 (1.04, 3.11)	1.85 (1.07, 3.21)
						<i>P</i> -interaction = 0.69568	<i>P</i> - interaction = 0.73121

Supplementary Table 4: Agreement between Oncotype DX recurrence scores from the Georgia Cancer Registry and Genomic Health Inc., among non-Hispanic White and non-Hispanic Black women diagnosed with a HR+/HER2– breast cancer in Georgia (2010–2014).

Georgia Cancer Registry	Genomic Health			
	Missing	Low	Intermediate	High
Missing	6331	867	483	102
Low	109	2149	16	0
Intermediate	60	11	1294	6
High	160	130	72	291